Research Reference
Adamax
Adamantane-modified Semax analog — cognitive research (no validated dose)
Research & educational purposes only. BioMaxFit does not sell, promote, or represent peptides in any way. We are strictly educational and recommend working with your doctor on anything health-related. The information below comes from published research and documents what has been studied, not what should be done. Many of these compounds are investigational and not approved by the FDA; possession or use outside an authorized clinical trial may be illegal in your jurisdiction. This is not medical advice.
Adamax is an adamantane-modified Semax analog sold as a 10 mg lyophilized vial. The essential caveat: there is no validated human dose for Adamax and no published Adamax dosing study of any kind. Every number is either a community/vendor convention or a figure borrowed from the Semax parent literature.
That distinction matters because Semax itself does have clinical dosing data — intranasal doses in the single-digit-milligram-per-day range were used for stroke recovery in Russian practice (Gusev et al., 1999). But those are Semax doses, for a medical indication, in patients — not Adamax doses for cognitive enhancement in healthy people. The adamantane-modified molecule has never been dose-ranged in a published study, so its potency relative to Semax (vendors claim 2–3x, unverified) is genuinely unknown.
Adamax is an investigational drug not approved by the FDA.
Dosing Reference
Reconstitution
Add 2 mL bacteriostatic water to the 10 mg vial. Resulting concentration: 5 mg/mL.
| Dose | Syringe Units | mL Volume | Schedule |
|---|---|---|---|
| 100 mcg | 2 units | 0.02 mL | Once daily or every other dayCommunity/vendor convention |
| 250 mcg | 5 units | 0.05 mL | Once daily or every other dayCommunity/vendor convention |
| 300 mcg | 6 units | 0.06 mL | Once daily or every other dayUpper community range |
Math assumes U-100 insulin syringes (1 mL = 100 units). Verify your syringe matches before use. Round half-units to the nearest visible mark.
Reconstitution
For a 10 mg vial: with 1 mL BAC water, concentration is 10 mg/mL; with 2 mL, 5 mg/mL; with 5 mL, 2 mg/mL. A ~250 mcg dose at 5 mg/mL draws to 5 units (0.05 mL); at 2 mg/mL, 12.5 units (0.125 mL). A more dilute reconstitution makes small volumes easier to measure.
No compound-specific stability data exists for reconstituted Adamax; community practice follows general research-peptide conventions (refrigerate, use within a few weeks, protect from light).
Cycling Protocol
Community convention describes ~2–4 weeks on, then a break. There is no validated cycle length for Adamax. The frequency and cycle figures are community/vendor conventions, not the output of any dose-ranging study.
Routes of Administration
Community sources describe two routes:
Subcutaneous: The other commonly reported route from a reconstituted vial.
Vendors frame the adamantane group as improving blood-brain-barrier penetration, which some community users cite as a reason to prefer lower or less-frequent doses than Semax — but no comparative pharmacokinetic study of Adamax versus Semax exists to confirm any route or dose advantage.
Stacking Protocols
Community sources commonly discuss the Semax family alongside other research nootropics — for example pairing a Semax-type peptide with Selank (positioned as anxiolytic) or with cholinergic compounds. These stacking patterns are community conventions carried over from Semax and have not been studied with Adamax. Combining unstudied research compounds compounds the uncertainty rather than resolving it, and there is no interaction or safety data for Adamax in any combination.
Side Effects & Safety
There is no published safety or adverse-event data for Adamax. The parent compound Semax has a long record of use in Russia and is generally described in that literature as well tolerated, but that record belongs to Semax, not to the adamantane-modified analog, and "generally well tolerated" is not the same as "characterized in controlled safety trials" for either.
Because Adamax has no toxicology, no pharmacokinetics, and no human safety data in the public literature, its risk profile is genuinely unknown. Decisions about an unapproved, uncharacterized research compound are matters for a licensed physician.
Research Basis
The per-administration figures (~100–300 mcg), the frequency, and the cycle lengths are community and vendor conventions, not the output of any dose-ranging study. They appear to be scaled down from typical Semax nasal doses on the assumption — promoted by sellers — that Adamax is more potent and longer-acting. That assumption has not been tested in any published research.
The only rigorously documented dosing in this family is Semax's, established for a medical indication (acute ischemic stroke) in a clinical setting (Gusev et al., 1999, PMID 10358912), not for cognitive enhancement in healthy users. Extrapolating from a stroke-recovery protocol to a healthy-user nootropic dose has no evidentiary support. The honest bottom line: nobody has published what an effective or safe Adamax dose is.